Zoetis Q3 Earnings Beat, Companion Animal Segment Growth Gives Confidence Into 2025: Analyst

On Monday, Zoetis Inc’s ZTS third-quarter 2024 adjusted EPS increased 16% year over year to $1.58, beating the consensus of $1.46.

The animal health firm reported sales of $2.39 billion, up 11%, beating the consensus of $2.29 billion.

On an operational basis, revenue for the third quarter of 2024 increased 14% compared with the third quarter of 2023.

Also Read: Elanco’s Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy

“Building on the strong momentum from the first half of the year, we are proud to have delivered another excellent quarter, fueled by our diverse, durable, and science-driven portfolio and our customer obsession that underscore our market leadership,” said Kristin Peck, Chief Executive Officer of Zoetis.

“We achieved 15% revenue growth in the U.S. and 13% operational revenue growth internationally, with both our companion animal and livestock portfolios seeing impressive global operational growth, 15% and 11%, respectively.”

Guidance: Zoetis raised its 2024 revenue guidance to $9.2 billion—$9.3 billion, compared to prior guidance of $9.1 billion—$9.25 billion and consensus of $9.194 billion. This is equivalent to an operational growth of 10% %- 11%.

Zoetis raised the 2024 adjusted EPS to $5.86-$5.92 versus prior guidance of $5.78-$5.88 and consensus of $5.82.

The company sees an adjusted net income of $2.67 billion-$2.695 billion, reflecting operational growth of 13.5%-14.5, with a reported net income of net income between $2.435 billion-$2.450 billion.

William Blair writes, “We view companion animal as the main driver of sentiment for shares and were encouraged to see 15% global growth in the segment despite concerns about competition and end-market noise.”

The analyst reaffirms an Outperform rating based on Zoetis’s third-quarter results, which initially appear to support the expectation for double-digit EPS growth in 2025.

Guidance and insights for 2025 provided during 2024 earnings will be the main factor driving valuation growth, William Blair analyst writes.

Price Action: ZTS stock is down 3.88% at $174.86 at last check Monday.

Read Next:

• Viking Therapeutics’ Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety

Photo by huoadg5888 via Pixabay